Pharma stocks fell after reports that the Trump administration may impose tariffs—potentially up to 100%—on drugmakers not ensuring low pri...

According to analysts, the sale of Glenmark Life could impact the profitability of Glenmark Pharma in FY25 but lower interest payments coul...

Glenmark Pharmaceuticals has entered into a definitive agreement with Nirma to divest a 75% stake in Glenmark Life Sciences for Rs 5,651.5 ...

The company attributed the net profit drop to an exceptional item of Rs 52 crore in the quarter that comprises remediation cost of manufact...

For the fourth quarter of FY23, Glenmark’s consolidated revenue was at Rs. 3374 crore as against Rs.3019 crore in the same quarter of previ...

The brokerage values Glenmark Pharma on a 13 times 12 month forward earnings basis to arrive at a price target of Rs 430.

The company had posted a net profit of Rs 414 crore in the July-September quarter a year ago.

Net sales of the company stood at Rs 2,763.73 crore, up 8.81 per cent.

Brokerage firm Prabhudas Lilladher said in a research note that the country might even go for a currency devaluation.

Credit Suisse believes that the pharma stock is already pricing in the best case scenario, which includes sustenance of profitability from ...

Pharma stocks are trading at extremely high valuations and, thus, could especially be vulnerable to any disappointment, says Bodke.

Depreciation of the Russian currency poses a risk to the profitability of Indian pharma companies such as Dr Reddy's, Glenmark and Ranbaxy.

The firm had posted a net profit of Rs 208.58 crore during the same period of previous fiscal, Glenmark Pharma said.

Cipla, Glenmark look very attractive. These companies are exhibiting very strong growth of more than 20% year on year based on global gener...

Satish Betadpur, CFA, Global Research Director, Independent International Investment Research, takes his picks on the midcap space on an ET...

Emkay Share and Stock Brokers has initiated coverage on Glenmark Pharma with a ‘buy’ rating for a target price of Rs 608, an upside of 35 p...

Glenmark Pharmaceuticals’ much-hyped asthma research molecule Oglemilast (code name GRRC 3886), is witnessing slower clinical progress, put...